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Programmed death-1 (PD-1) is a coinhibitory inducible receptor 
present on T-cells and macrophages. Tumor cells with increased 
programmed death ligand-1 (PD-L1) are believed to escape immu-
nity through activation of PD-1/PD-L1 pathway and suppression of 
effector-immune responses. Recent strategies targeting the PD-1/
PD-L1 axis have shown promising results in patients with several 
tumors types, including lung carcinomas. Preliminary data suggest 
that PD-L1 protein expression might have predictive response to 
such therapies. Sarcomatoid carcinomas (SCs) of the lung include 
rare subtypes of poorly differentiated non–small-cell lung carcino-
mas of high grade and aggressive behavior. The biology of these 
neoplasms is poorly understood and they frequently show increased 
local inflammatory and lymphocytic infiltration. Here, we report the 
expression of PD-L1 in 13 SCs from two large retrospective lung 
cancer cohorts. Using automated quantitative immunofloresence 
and a mouse monoclonal antibody directed against the extracellular 
domain of PD-L1, we show that 9 of 13 patients (69.2%) with SCs 
are positive for PD-L1 and their levels are higher than in conven-
tional non–small-cell lung carcinoma. These results provide rationale 
for the potential use of targeted immunotherapy in lung SCs.
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(J Thorac Oncol. 2013;8: 803-805)
Programmed death-1 (PD-1) is a negative regulator of T-lymphocytes and acts as a coinhibitory receptor to pre-
vent off target immune activation.1 Tumor cells from diverse 
locations overexpress PD-1 receptor ligand called increased 
programmed death ligand-1 (PD-L1) (also B7-h1 or CD274). 
Up-regulation of PD-L1 by neoplastic cells allows tumors to 
escape the effector-immune responses. Recently, clinical trials 
using monoclonal antibodies targeting the PD-1/PD-L1 axis 
show promising antitumor activity in several malignancies, 
including lung carcinomas.2,3 Preliminary data from these 
trials suggest that tumor PD-L1 expression predicts response 
to these treatments.
Sarcomatoid carcinoma (SC) is a rare form (0.3%–1.3% 
of all lung carcinomas) of poorly differentiated non–small-cell 
lung carcinoma (NSCLC) containing a component of malignant 
mesenchymal differentiation. According to the last World Health 
Organization classification, SCs comprise five histopathologic 
subtypes: pleomorphic carcinoma (PC), spindle-cell carcinoma 
(SCC), giant cell carcinoma (GCC), carcinosarcoma, and 
pulmonary blastoma.4 Combined lesions (e.g., PC) include areas 
of conventional NSCLC (e.g., squamous, adenocarcinoma, 
or large-cell carcinoma) and the more common sarcomatous 
elements are SCC and GCC. SCCs are characterized by the 
presence of fascicles and nests of highly atypical elongated 
cells. GCCs are characterized by large pleomorphic mono- or 
multinucleated giant tumor cells, and mixed inflammatory 
infiltrates, composed predominantly of neutrophils and 
lymphocytes. In addition, engulfment of intact inflammatory 
cells by giant tumor cells (a phenomenon called emperipolesis) 
is a distinctive finding. These tumors are aggressive and resistant 
to chemotherapy and radiotherapy.5 Little is known about the 
biology of these neoplasms and the mechanism of chemo or 
radio-resistance and progression. Here, we measured the levels 
of PD-L1 protein using the AQUA method of quantitative 
immunofluorescence in 13 SCs samples from two retrospective 
lung cancer cohorts. Our results show that SCs show higher 
PD-L1 levels than other NSCLC, supporting a potential for the 
use of anti-PD-1/PD-L1 targeted therapies.
MATERIALS AND METHODS
Formalin-fixed paraffin-embedded tissue samples 
(FFPE) from 13 SCs were selected from two retrospective 
lung cancer cohorts, including patients with NSCLC from 
the Yale University and Sotiria General Hospital in Greece 
(December 1988 and October 2003). The cohort descrip-
tions were previously communicated.6,7 The 13 SCs exam-
ined were part of a broader study where 458 patients were 
evaluable for PD-L1 measurement. All the specimens were 
evaluated in a tissue microarray (TMA) format. Human 
placenta and tonsil were included as positive controls for 
endogenous PD-L1, along with cores from FFPE parental 
and PD-L1 overexpressing Mel624 cells. Culture conditions 
and cell-line TMA construction were performed, as reported 
elsewhere.8 TMA sections were deparaffinized in an oven 
for 30 minutes at 60°C followed by two serial xylenes incu-
bations. Sections were then rehydrated in graded alcohols, 
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and subjected to antigen retrieval using tris-EDTA buffer 
with 0.05% Tween (pH = 9.0) and boiled for 20 minutes 
at 102°C in a pretreatment module (Lab Vision, Fermont, 
CA). Slides were incubated with ACE block at room tem-
perature for 10 minutes and exposed overnight at 4°C to 
a mouse monoclonal primary PD-L1 antibody (clone 5H1; 
Dr. Lieping Chen, Yale University, New Haven, CT) at 1:500 
dilution, and a rabbit monoclonal antihuman pancytokeratin 
antibody at 1:50 (AE1/AE3, M3515; DAKO, Carpinteria, 
CA). Sections were incubated for 1 hour at room tempera-
ture with Alexa 546-conjugated goat antirabbit secondary 
antibody (A11003; Molecular Probes, Eugene, OR) diluted 
1:100 in mouse EnVision amplification reagent (K4003; 
Dako). Cyanine 5 (Cy5) directly conjugated to tyramide 
(FP1117; Perkin-Elmer, Boston, MA) at a 1:50 dilution 
was used for antibody detection. Prolong mounting medium 
(ProLong Gold, P36931; Molecular Probes) containing 
4′,6-diamidino-2-phenylindole was used to highlight nuclei. 
Automated quantitative fluorescence analysis (QIF/AQUA) 
was used for PD-L1 measurements, allowing objective 
measurement of protein levels within user defined cellular 
compartments, as described in detail elsewhere.9 AQUA 
scores of PD-L1 protein in each histospot were measured 
in the area of the tumor mask (defined by the cytokeratin 
positive compartment). Comparisons of mean AQUA scores 
of PD-L1 were performed using Mann–Whitney test and 
GraphPad Prism software.
RESULTS
The levels of PD-L1 were measured using quantitative 
fluorescence analysis (QIF) in the lung cases and in control 
preparations (Fig. 1). Specificity of the assay was tested in 
TMA-based FFPE preparations containing term human pla-
centa and Mel624 cell lines with or without PD-L1 trans-
fection. As expected, PD-L1 signal was detected only in the 
placental trophoblastic cells (cytokeratin positive compart-
ment) and in Mel624 transfectants, but not in the mesenchymal 
areas of the chorionic villi (Vimentin positive compartment) 
or in parental Mel624 cells (Fig. 1B). In the control prepara-
tions, PD-L1 staining was relatively homogenous and with a 
predominant perinuclear staining pattern.
In agreement with previous reports,5 the studied SCs 
included a relatively large proportion of GCCs showing char-
acteristic discohesive and highly atypical giant tumor cells, 
some of them multinucleated and with prominent neutrophilic 
infiltration (Fig. 1A hematoxylin & eosin stain; left panels). 
The positivity of pancytokeratin staining in atypical cells 
FIGURE 1.  Sarcomatoid lung carcinomas show increased PD-L1 protein levels. A, Representative microphotographs showing 
PD-L1 and CK positivity in giant cell lung carcinoma. Left panels include hematoxylin & eosin-stained preparations at 200× 
(upper) and 400× magnification (lower panel). Giant cell carcinomas show characteristic lack of typical epithelial cohesive-
ness, a prominent mixed inflammatory infiltrate and bizarre giant tumor cells with single or multiple nuclei and focal leuko-
cyte engulfment (emperipolesis, arrows). The right panels show fluorescence captions of PD-L1 (upper, red channel) and CK 
(lower, green channel) positivity of the same sample. Nuclei were stained with 4′, 6-diamidino-2-phenylindole (blue channel). 
B, Representative fluorescence microphotographs showing PD-L1 staining in formalin-fixed paraffin-embedded term human 
placenta (upper panels) and Mel624 transfectants (lower panels). PD-L1 positivity in placental samples was restricted to the 
trophoblastic cells (CK positive compartment;right panel) and absent in the stromal areas (vimentin positive compartment; Vim, 
left panel). Bar = 100 µm. In the cell lines, PD-L1 signal was evident with a perinuclear or membranous pattern only in PD-L1-
transfected Mel624 cells (bottom right panel) but not in parental cells (bottom left panel). Bar = 50 µm. C, Graph showing 
mean ± standard error mean PD-L1 AQUA scores in conventional NSCLC (left bar) and in Sarcomatous carcinomas (right bar). 
AQUA scores are expressed as arbitrary units (AU). Cases were measured in the same preparations. The number of cases in each 
group is indicated within each bar. **p < 0.01. AQUA; automated quantitative fluorescence analysis; PD-L1, programmed death 
ligand-1; CK, cytokeratine; NSCLC, non–small-cell lung cancer.
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confirmed the epithelial nature of the lesion, and PD-L1 posi-
tivity was identified in both tumor and stromal cells (Fig. 1A; 
right panels).
Of 13 SCs cases, 10 were GCCs, one SCC, one car-
cinosarcoma and one PC (Table 1). Subjects affected by 
SC were predominantly men (10 of 13) with average 60.2 
years, diverse clinical stages at presentation and history of 
tobacco use (Table 1). Of 13 SCs, nine (69.2%) were posi-
tive for PD-L1, and as depicted in Figure 1C, PD-L1 levels 
were approximately 40% higher in SCs than in conventional 
NSCLC (AQUA score 138 and 190, respectively p < 0.01). 
Only 122 of 445 conventional NSCLC (27.4%) in the studied 
cohorts were positive for PD-L1.
DISCUSSION
SC is a rare subtype of NSCLC with a poorly under-
stood biology and ominous outcome. The identification of 
actionable molecular targets for such infrequent and aggres-
sive diseases is critical for design of new clinical trials.4 In 
agreement with previously reported studies,10–12 the present 
data show that SC patients comprise predominantly adult 
male smokers with nonmetastatic disease at diagnosis. Among 
SCs, GCC represents a frequent histologic tumor component 
or subtype, and shows characteristic morphology with highly 
atypical discohesive large tumor cells, and increased inflam-
matory and lymphocytic response.
Increased tumor infiltration by neutrophils and lympho-
cytes in SCs suggest the presence of strong local antitumor 
immune responses. Despite the presence of rich inflammatory 
infiltrates patients with SCs have worse outcomes compared 
with other histologic subtypes of NSCLC. Elevated expression 
of PD-L1 by SC cells might account for this apparent contra-
diction because local inactivation of effector-immune cells 
through PD-1 receptor signaling could ultimately enhance 
the disease progression. Additional local immune inhibitory 
mechanisms, such as infiltration by specific immune inhibi-
tory cells (e.g., T regulatory cells and myeloid-derived sup-
pressor cells), production of inhibitory cytokines (e.g., IL-6, 
IL-10, transforming growth factor-β), and activation of other 
T-cell coinhibitory pathways (e.g., CTLA-4, PD-L2, IDO-
1) might also participate. Future studies will be required to 
clarify this.
Compared with conventional NSCLC, SCs are more 
aggressive and cytotoxic chemotherapy is generally ineffective. 
Recent advances in our understanding of the mechanisms 
of immune escape of tumors paved way for new therapeutic 
strategies. Although lung carcinomas have traditionally been 
considered to be poorly immunogenic, PD-1/PD-L1 interaction 
has been recognized as a key mechanism of immune evasion 
in NSCLC.1,13,14 To our knowledge, this is the first report 
measuring PD-L1 protein levels in SCs, and the results suggest 
the possibility of using novel immunotherapy approaches such 
as PD-1/PD-L1 blockers in this otherwise difficult to treat 
disease.
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TABLE 1.  Main Clinicopathological Characteristics of 
Subjects with Sarcomatous Carcinomas
Age Sex Stage Smoking Histology
PD-L1 
Status
48 Female IB Yes Giant cell carcinoma Negative
66 Male IIB NA Giant cell carcinoma Negative
61 Male IIB Yes Giant cell carcinoma Negative
64 Male IIIA Yes Giant cell carcinoma Negative
61 Male IIIB Yes Giant cell carcinoma Positive
47 Male IV Yes Giant cell carcinoma Positive
54 Male IIB Yes Giant cell carcinoma Positive
55 Male IB Yes Giant cell carcinoma Positive
65 Male IB Yes Giant cell carcinoma Positive
42 Female IIB Yes Giant cell carcinoma Positive
83 Male IB NA Spindle-cell carcinoma Positive
66 Male IA NA Carcinosarcoma (non– 
small-cell lung cancer  
and spindle/chondroid)
Positive
71 Female IB NA Pleomorphic carcinoma 
(adenocarcinoma and 
giant/spindle cell)
Positive
NA, not available; PD-L1, programmed death ligand-1.
